Dinaciclib treatment demonstrated antitumor activity in @ of @ patients with estrogen receptor-positive and human epidermal growth factor receptor @-negative metastatic breast cancer ( @ confirmed and @ unconfirmed partial response ) , as well as acceptable safety and tolerability .